Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk my...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Haematologica
Hoofdauteurs: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Levy, Richard S., Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael W.N., Miller, Carole B., Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth O., Lyons, Roger M., Raza, Azra, Vaddi, Kris, Sun, William, Peng, Wei, Sandor, Victor, Kantarjian, Hagop
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Ferrata Storti Foundation 2015
Onderwerpen:
Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4380721/
https://ncbi.nlm.nih.gov/pubmed/25616577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.115840
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items